Abstract: A deep metagenomic sequencing of more than 1000 individual gut microbiomes, coupled with detailed long-term diet, fasting, and same-meal postprandial cardiometabolic blood markers analyses, is described. Strong associations between a set of microbes and specific nutrients, foods, food groups, and general dietary indices are demonstrated. Microbial biomarkers of obesity were reproducible across cohorts, but blood markers of cardiovascular disease and impaired glucose tolerance were more strongly associated with microbiome structures. Panels of intestinal microbial species associated with different conditions and/or habits are identified, enabling stratification of the gut microbiome into generalizable health levels among individuals even without clinically manifest disease.

Abstract: Techniques are disclosed herein for generating microbiome fingerprints, dietary fingerprints, and microbiome ancestry. Microbiome data associated with an individual is analyzed to generate a microbiome fingerprint, and a dietary fingerprint for a user. A “microbiome fingerprint” uniquely identifies the microbiome of a user at a particular point in time and is based on a combination of different profiles generated from the microbiome data. The dietary fingerprint identifies how the microbiome of a user is associated with one or more different indexes, such as a dietary index and/or a particular characteristic (e.g., a Mediterranean diet index, a vegetarian diet index, a fast food index, an internal fat index, a fat-digesting index, a carbohydrate-digesting index, a health index, a fasting index, a ketogenic index, . . . ). The microbiome data may also be utilized to determine microbiome ancestry for the user that indicates other users to which the user is related to.

Abstract: Methods, reagents and compositions thereof for predicting risk for NORA onset in susceptible individuals, diagnosing NORA onset, and/or evaluating efficacy of a therapeutic regimen for treating RA are described herein. Determining the amount of at least one of SEQ ID NOs: 1-19 and/or at least one of a KO presented in either of Tables S4 or S5 serves as a biomarker for the above indications.